Tchaikapharma High Quality Medicines AD (THQM) Stock Overview
Develops, manufactures, and sells medicines in Bulgaria. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Risk Analysis
No risks detected for THQM from our risk checks.
THQM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Tchaikapharma High Quality Medicines AD Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | лв17.70 |
52 Week High | лв17.70 |
52 Week Low | лв7.75 |
Beta | 0.031 |
1 Month Change | 4.73% |
3 Month Change | n/a |
1 Year Change | 5.66% |
3 Year Change | 26.18% |
5 Year Change | 49.47% |
Change since IPO | 677.09% |
Recent News & Updates
Tchaikapharma High Quality Medicines AD's (BUL:THQM) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Feb 26Tchaikapharma High Quality Medicines AD (BUL:THQM) May Have Run Too Fast Too Soon With Recent 27% Price Plummet
Feb 26Recent updates
Shareholder Returns
THQM | BG Pharmaceuticals | BG Market | |
---|---|---|---|
7D | 0% | -2.3% | -0.6% |
1Y | 5.7% | -14.2% | 10.4% |
Price Volatility
THQM volatility | |
---|---|
THQM Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 5.0% |
Market Average Movement | 3.2% |
10% most volatile stocks in BG Market | 5.3% |
10% least volatile stocks in BG Market | 1.7% |
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 216 | Biser Georgiev | www.tchaikapharma.com |
Tchaikapharma High Quality Medicines AD develops, manufactures, and sells medicines in Bulgaria. It offers anesthetic, anti-inflammatory and anti-rheumatic, antibiotic, cardiovascular system, digestive system, diabetes and metabolism, nervous system, OTC, respiratory system, oncology, and other medicines. The company was founded in 1999 and is headquartered in Sofia, Bulgaria.
Tchaikapharma High Quality Medicines AD Fundamentals Summary
THQM fundamental statistics | |
---|---|
Market cap | лв1.70b |
Earnings (TTM) | лв6.47m |
Revenue (TTM) | лв58.44m |
Is THQM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
THQM income statement (TTM) | |
---|---|
Revenue | лв58.44m |
Cost of Revenue | лв12.86m |
Gross Profit | лв45.58m |
Other Expenses | лв39.11m |
Earnings | лв6.47m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
Earnings per share (EPS) | 0.067 |
Gross Margin | 77.99% |
Net Profit Margin | 11.07% |
Debt/Equity Ratio | 8.9% |
How did THQM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/10/17 22:09 |
End of Day Share Price | 2025/10/08 00:00 |
Earnings | 2025/06/30 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tchaikapharma High Quality Medicines AD is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.